Targeted Radiotherapy
About us
- Team
- Contact
- Directions
News
Careers
Search
Menu Menu

Blog - Latest News

You are here: Home1 / 20202 / Debiopharm expands its radiopharmaceutical footprint with an exclusive...

25. March 2020/by imken

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

Share this entry

Share on Facebook
Share on Twitter
Share on Pinterest
Share on LinkedIn
Share on Tumblr
Share on Vk
Share on Reddit
Share by Mail

https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png 0 0 imken https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png imken2020-03-25 11:10:502020-05-12 16:40:50Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

© 3B Pharmaceuticals
Imprint
Data privacy statement

3B Pharmaceuticals GmbH
Magnusstraße 11
D-12489 Berlin
Tel: +49 (0)30 / 63 92 - 43 17
Fax: +49 (0)30 / 63 92 - 43 16
info@3b-pharma.com

Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program...3B Pharmaceuticals hosts industry symposium on radiopharmaceutical innovation...